VENLO, the Netherlands, May 2, 2017 /PRNewswire/ --
- Delivering on growth ambitions with good Q1 2017 performance:
o Net sales $307.7 million (+3% actual); adjusted net sales $308.3 million (+3% actual, +6% CER vs. +4-5% CER guidance)
o EPS $0.08; adjusted EPS $0.20 ($0.21 CER), adjusted EPS excl. restructuring charge $0.22 ($0.22 CER vs. $0.21-0.22 CER guidance)
o Free cash flow rises 46% to $44.2 million
- Dr. Håkan Björklund joins QIAGEN Supervisory Board
- QIAGEN reaffirms full-year 2017 outlook for 6-7% CER sales growth and adjusted EPS target before restructuring costs of $1.25-1.27 CER
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the first quarter 2017, delivering on goals for improvements in net sales and adjusted earnings.
"QIAGEN delivered a good start into 2017, and this has reaffirmed our confidence in achieving full-year goals for strong sales growth and a double-digit increase in adjusted earnings per share," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. "The progress we are making in 2017 is providing further support for QIAGEN's ambitions for faster sales growth, double-digit earnings gains and increased cash flows through 2020.
Click here for the full press release
#GeneReader #QuantiFERON #Maccura #JAK2
Vice President Corporate Communications and Investor Relations
Dr. Sarah Fakih
Associate Director Investor Relations
Dr. Thomas Theuringer
Senior Director Public Relations and Digital Communications
Download the QIAGEN Investor Relations App
SOURCE QIAGEN N.V.